Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Indoco Remedies' Baddi Unit-I manufacturing facility has successfully received EU GMP certification from the Malta Medicines Authority. This certification confirms compliance with Good Manufacturing Practice requirements for its solid oral dosage form production.
May 14 2026 11:05:00
Indoco Remedies Limited
Indoco Remedies announced the slump sale of its Ophthalmic Division to Sunways (India) Private Limited for a cash consideration of Rs. 110 crore. This strategic move aims to enable the company to focus on its core therapeutic areas.
May 01 2026 14:05:00
Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
Indoco Remedies has divested its Ophthalmic Division to Sunways (India) Private Limited for a consideration of Rs. 110 crore. This strategic move aims to enable the company to focus on its core therapeutic areas.
Apr 30 2026 19:04:00
Indoco Remedies Limited
Indoco Remedies divested its ophthalmic business division to Sunways (India) Private Limited for Rs. 110 crore. This strategic move allows Indoco to focus on its core therapeutic areas.
Apr 30 2026 19:04:00
Indoco Remedies Limited
Indoco Remedies Limited approved the transfer of its ophthalmic business in India and Africa to Sunways (India) Private Limited. This strategic move aims to sharpen Indoco's focus on core therapeutic areas with higher potential.
Apr 30 2026 19:04:00
Indoco Remedies Limited
Indoco Remedies Limited's Board approved the slump sale of its Ophthalmic Division, covering specific territories, to Sunways (India) Private Limited for Rs. 110 crores. This strategic divestment allows the company to focus on core therapeutic areas.
Apr 30 2026 18:04:00
Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
Indoco Remedies' Board approved the divestment of its Ophthalmic Division in India and other territories to Sunways (India) Private Limited via a slump sale for Rs. 110 crore. This strategic move aims to sharpen the company's focus on its core therapeutic segments.
Apr 30 2026 18:04:00
Read More